

## PRESS RELEASE

### **The CNMC cleared five mergers in October**

- All of them were approved in Phase I as they did not pose problems to competition in their respective markets.
- The sectors affected by the business mergers were ceramics, pharmaceuticals, hospitals, digital platforms, and renewable energies.

**Madrid, 6 November 2020** - The CNMC cleared a total of five mergers in October. All of them were authorised in Phase I as they did not entail risks to competition in their specific markets.

### [C/1119/20: NOMAR / ARGENTA & CIFRE](#)

#### **Nomar enhances its position in the ceramic sector**

On 13 October 2020, the CNMC authorised, in Phase I, the merger through which Nomar Patrimonial, S.L. gains exclusive control of Argenta Cerámica, S.L. and Cifre Cerámica, S.L.

Nomar is a Spanish holding company that produces and markets ceramics, particularly ceramic tiles, in the province of Castellón.

As for Argenta and Cifre, they are family businesses located in Castellón that manufacture the same types of products. Nomar's acquisition of both companies is interrelated, and was therefore analysed by the CNMC as a single file.

The merger gives rise to minor horizontal overlaps in the European market. In the case of the domestic market, the overlaps are greater, but the market is highly fragmented with a low degree of concentration, and many prominent companies remain in the market. There is also excess capacity and it is easy to change suppliers.

The merger also does not give rise to significant vertical overlaps or portfolio effects either, since the resulting entity will not have significant market power in any of the market segments in which it operates, and there are sufficient alternatives.

In light of the above, the CNMC does not view this merger as posing a threat to competition in the affected markets.

### [C/1129/20 EQT / IDEALISTA INTERNATIONAL](#)

#### **Fund manager EQT acquires the Idealista real estate portal**

On 20 October 2020, the CNMC authorised, in Phase I, the merger through which the investment fund EQT IX acquires exclusive control of Idealista International S.A.

*Unofficial document intended for the media. Not binding on the CNMC. Reproduction authorised only if the source is cited.*

EQT IX SCSp (EQT IX) is an investment fund of EQT, whose objective is to invest primarily in Europe.

Idealista International S.A. manages an online platform for real estate advertisements containing both private and professional listings, which operates in Spain, Portugal and Italy.

The CNMC is of the opinion that this merger does not pose a threat to effective competition in the affected markets in Spain, since there is no horizontal or vertical overlap between the activities of the parties to the merger.

### **C/1132/20 CHIESI FARMACEUTICI / NEGOCIO REVCovi**

#### **The pharmaceutical company Chiesi acquires the Revcovi drug therapies for treating the "ADA-SCID" rare hereditary immunodeficiency**

On 20 October 2020, the CNMC cleared, in Phase I, the merger by which Chiesi Farmaceutici S.P.A. acquires exclusive control over the global business for Revcovi.

Chiesi is a global pharmaceutical group based in Parma (Italy) that develops and manufactures therapeutic medicines for respiratory diseases, neonatology, special care and rare diseases.

Revcovi, owned by the Lediand Group, is an enzyme replacement therapy indicated for treating Severe Combined Immunodeficiency (ADA-SCID) in children and adults. SCID is an extremely rare inherited genetic disorder that is fatal if left untreated.

The CNMC does not regard this merger as posing a threat to competition in the affected markets given the zero overlap between the activities of the parties involved. Chiesi does not currently have any products in its portfolio that involve the same product market as Revcovi, nor does it have R&D lines for products to replace Revcovi. It also does not manufacture any of the components used to produce Revcovi.

### **C/1131/20 SECURE CAPITAL SOLUTIONS 2000 / HOSPITAL POLUSA**

#### **The Ribera Salud Group acquires a private hospital in Lugo**

On 27 October 2020, the CNMC authorised, in Phase I, the merger by which the Ribera Salud group gains exclusive control of Hospital Polusa.

The main activity of the Ribera Salud group is the ownership and/or private management of various hospitals and public primary health centres. It also provides clinical laboratory services to several public hospitals.

Hospital Polusa is a private hospital that provides services to both private and public patients in the area of Lugo, Cervo and Monforte de Lemos.

The merger is not expected to pose an obstacle to effective competition in the healthcare markets for public and private patients, or to the transfer or rental of healthcare facilities. The parties provide their services in different provinces, and

*Unofficial document intended for the media. Not binding on the CNMC. Reproduction authorised only if the source is cited.*

have a joint share in Galicia that is below 35%, which this merger increases by less than 5%. There are also other competitors at both the regional level (Grupo HM Hospitales, Grupo Quirón, VITHAS, and other private hospitals) and provincial level (Hospital Nuestra Señora de los Ollos Grandes).

### **[C/1130/20 Q-ENERGY/TORRESOL](#)**

#### **The Q-Energy fund acquires the solar energy production company Torresol**

On 27 October 2020, the CNMC authorised, in Phase I, the merger by which Q-Energy Private Equity acquires exclusive control of Torresol Energy Investments, S.A.

Torresol produces electricity from renewable solar thermal sources in the provinces of Seville and Cádiz.

The CNMC takes the view that this merger does not pose a threat to competition in the affected markets, since the parties involved in the merger have a low share in the markets in question (combined share of less than 15%) and the merger does not give rise to vertical overlaps with any market.

[List of mergers approved by the CNMC](#)

[More information on the merger analysis procedure](#)